Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)
Breast Cancer · 2023
DOI: 10.1007/s12282-022-01425-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Breast Cancer, 2023. Verfasst von Manabu Futamura und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. mfutamur@gifu-u.ac.jp. Hauptthemen laut MEDLINE: Breast Neoplasms, Neutropenia, Nanoparticles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Nanoparticle albumin-bound paclitaxel (nab-PTX) is a promising antibody partner for anti-human epidermal growth factor receptor 2 (HER2). We performed neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer (BC) using nab-PTX plus trastuzumab (T-mab) and pertuzumab (P-mab), followed by epirubicin and cyclophosphamide (EC).
Methods
In this multicenter phase II clinical trial (January 2019–July 2020), patients with stage I (T1c)-IIIB HER2-positive primary BC were treated with four cycles of nab-PTX plus T-mab and P-mab, followed by four cycles of EC. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints were clinical response rate (RR), adverse events (AE), and tumor-infiltrating lymphocytes (TILs) in biopsy samples.
Results
In total, 43 patients were enrolled (mean age, 54 years). Twenty-two patients had HER2, and 21 patients had luminal/HER2-subtypes. The overall pCR rate was 53.5% (23/43, 95% CI: 42.6–64.1%, p = 0.184), whilst the pCR for HER2 was 68.2% (15/22, 95% CI: 45.1–86.1) and 38.1% for luminal/HER2 (8/21, 95% CI: 18.1–61.6%). The RR was 100% [clinical (c) CR:25, partial response (PR): 18]. AEs (≥ G3) included neutropenia (23.3%), leukopenia (7.0%), liver dysfunction (7.0%), and peripheral neuropathy (4.7%) when nab-PTX was administered. EC administration resulted in leukopenia (34.2%), neutropenia (31.6%), and febrile neutropenia (15.8%). The TILs in preoperative biopsy samples were significantly higher in pCR compared to non-pCR samples.
Conclusion
Nab-PTX plus T-mab and P-mab induced a high pCR rate in HER2-positive BC, particularly in the HER2-subtype. Given that AEs are acceptable, this regimen is safe and acceptable as NAC for HER2-positive BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. mfutamur@gifu-u.ac.jp.
- Department of Surgery, Gihoku Kosei Hospital, Gifu, 501-2105, Japan.
- Department of Surgery, Gifu Prefectural General Medical Center, Gifu, Japan.
- Department of Breast Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
- Department of Breast Surgery, Gifu Municipal Hospital, Gifu, 500-8513, Japan.
- Department of Breast Surgery, Asahi University Hospital, Gifu, 500-8523, Japan.
Zitieren
APA
Futamura, M., Ishihara, K., Nagao, Y., Ogiso, A., Niwa, Y., Nakada, T., Kawaguchi, Y., Ikawa, A., Kumazawa, I., Mori, R., Kitazawa, M., Hosono, Y., Kuno, M., Kawajiri, M., Nakakami, A., Takeuchi, M., Morikawa, A., Tokumaru, Y., Katagiri, Y., …, & Matsuhasih, N. (2023). Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast Cancer. https://doi.org/10.1007/s12282-022-01425-2
Vancouver
Futamura M, Ishihara K, Nagao Y, Ogiso A, Niwa Y, Nakada T, et al. Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast Cancer. 2023. doi:10.1007/s12282-022-01425-2
BibTeX
@article{Futamura2023,
author = {Futamura, Manabu and Ishihara, Kazuhiro and Nagao, Yasuko and Ogiso, Atsuko and Niwa, Yoshimi and Nakada, Takumi and Kawaguchi, Yoshihiro and Ikawa, Ai and Kumazawa, Iwao and Mori, Ryutaro and Kitazawa, Mai and Hosono, Yoshiki and Kuno, Masashi and Kawajiri, Mana and Nakakami, Akira and Takeuchi, Makoto and Morikawa, Akemi and Tokumaru, Yoshihisa and Katagiri, Yasuo and Asano, Yoshimasa and Mushika, Yoshinori and Shimokawa, Toshio and Matsuhasih, Nobuhisa},
title = {Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04)},
journal = {Breast Cancer},
year = {2023},
doi = {10.1007/s12282-022-01425-2}
}
EUVIMED